Results 311 to 320 of about 263,255 (408)

Specific blockade of plasma membrane Ca2+ pump by antisense-oligonucleotides.

, 1996
Ken‐Ichi Furukawa, Miwa Shiratori, Satoshi Sasamura, Yasushi Ohizumi   +3 more
openalex   +1 more source

Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract Individuals with Down syndrome (DS) have a genetically determined form of Alzheimer's disease (AD) due to the amyloid precursor protein (APP) gene dose effect. Nearly all individuals with DS develop AD pathology by age 40. Although dementia is rare before this age, its incidence rises sharply thereafter.
Isabel Barroeta, Laura Videla, María Carmona‐Iragui, Juan Fortea, Michael S. Rafii   +4 more
wiley   +1 more source

Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS. [PDF]

Bioanalysis
Jiang D, Li P, Yuan L.
europepmc   +1 more source

c-fos antisense oligonucleotide infusion into mouse striatum blocks methamphetamine-induced locomotor activity in a reversible manner

, 1996
Tadashi Umekage, Misako Namima, Kouji Fukushima, Souhei Sugita, Yasuhiro Watanabe   +4 more
openalex   +1 more source

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population‐based multimodal biomarker cohort studying AD's natural history and clinical trials in DS.
Laura Videla, Bessy Benejam, Isabel Barroeta, Susana Fernandez, Miren Altuna, Javier Arranz, Íñigo Rodríguez‐Baz, José Enrique Arriola‐Infante, Lucía Maure‐Blesa, Laura del Hoyo Soriano, Ignacio Illán‐Gala, Teresa Estellés, Aida Sanjuan, Lídia Vaqué‐Alcázar, Mateus Rozalem Aranha, Alejandra O. Morcillo‐Nieto, Sarah Erzsebet Zsadanyi, Maria Franquesa‐Mullerat, Sílvia Valldeneu, María Belén Sánchez‐Saudinós, Concepción Padilla, Mireia Carreras, Oriol Lorente, Natalia Valle‐Tamayo, Érika Sánchez‐Aced, Oriol Dols‐Icardo, Sònia Sirisi, Laia Muñoz, Soraya Torres, Shaima El Bounasr El Bennadi, Oriol Sánchez, Diana Garzón, Laia Ribas, Sumia Elbachiri, Cecilia Mota, Mireia Tondo, Valle Camacho, Sandra Giménez, Constance Delaby, Olivia Belbin, María Florencia Iulita, Víctor Montal, Jordi Pegueroles, Eduard Vilaplana, Jordi Clarimón, Sofía González‐Ortiz, Laura Molina‐Porcel, Iban Aldecoa, Daniel Alcolea, Alexandre Bejanin, Sebastià Videla, Rafael Blesa, Alberto Lleó, María Carmona‐Iragui, Juan Fortea   +54 more
wiley   +1 more source

Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction

, 2000
Qingli Cheng, Xiangmei Chen, Feng Li, Hongli Lin, Yi-Zhou Ye, Bo Fu   +5 more
openalex   +1 more source

The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer's disease

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract Noninvasive brain stimulation (NIBS) techniques, such as repetitive transcranial magnetic stimulation (rTMS), are promising candidate therapeutics for Alzheimer's disease (AD). We review the evidence supporting the fundamental mechanisms of action of rTMS treatments in AD.
Annibale Antonioni, Alessandro Martorana, Emiliano Santarnecchi, Harald Hampel, Giacomo Koch   +4 more
wiley   +1 more source

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. [PDF]

Cardiovasc Res
Modder M, Het Panhuis WI, Li M, Afkir S, Dorn AL, Pronk ACM, Streefland TCM, Lalai RA, Pierrou S, Nilsson SK, Olivecrona G, Kooijman S, Rensen PCN, Schönke M.   +13 more
europepmc   +1 more source

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) [PDF]

, 2018
et al,, Picus, Joel
core   +1 more source

Brain Metabolic Features of FUS‐ALS: A 2‐[18F]FDG‐PET Study

Annals of Neurology, Volume 97, Issue 6, Page 1134-1143, June 2025.
Objective We aimed at evaluating the brain metabolic features of fused in sarcoma amyotrophic lateral sclerosis (FUS‐ALS) compared with sporadic ALS (sALS), using 2‐[fluorine‐18] fluoro‐2‐deoxy‐D‐glucose positron emission tomography (2‐[18F]FDG‐PET). Methods We employed the 2‐sample t‐test model of SPM12, implemented in MATLAB, to compare 12 FUS‐ALS ...
Antonio Canosa, Umberto Manera, Rosario Vasta, Grazia Zocco, Francesca Di Pede, Sara Cabras, Filippo De Mattei, Francesca Palumbo, Barbara Iazzolino, Emilio Minerva, Luca Sbaiz, Maura Brunetti, Salvatore Gallone, Maurizio Grassano, Enrico Matteoni, Giulia Polverari, Giuseppe Fuda, Federico Casale, Paolina Salamone, Giovanni De Marco, Giulia Marchese, Cristina Moglia, Andrea Calvo, Marco Pagani, Adriano Chiò   +24 more
wiley   +1 more source